Quantcast

Industry news that matters to you.  Learn more

Blood-based Diagnostic Assay from Biodesix Measures Immunotherapy Biomarker PD-L1

New data from Biodesix® evaluating an assay in development demonstrated the potential to measure circulating PD-L1 through mRNA in blood through multiplexed droplet digital™ PCR (ddPCR, Bio-Rad, Inc.) detection. The assay uses proprietary RNA isolation methods consistent with Biodesix’s commercialized GeneStrat® ALK, ROS1, and RET variant tests. Existing immunohistochemistry (IHC) PD-L1 tissue tests are used to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the ASCO-SITC Clinical Immuno-Oncology Program in Orlando, Florida.

Candidate Biomarkers for Postmenopausal Osteoporosis

An article published in Experimental Biology and Medicine (Volume 242, Issue 2, January, 2017) reports a new method for identifying women at risk for osteoporotic fractures. The study, led by Dr. Katre Maasalu, Associate Professor and orthopedic surgeon from Traumatology and Orthopeadic Clinic of Tartu University, demonstrated that a biomarker panel consisting of six genes could distinguish postmenopausal women with osteoporosis, a major risk factor for fracture, from those without osteoporosis.

Bioline Launches Latest ISOLATE II miRNA and RNA Purification Kits

Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the latest five kits in the high performance ISOLATE II nucleic acid purification range – ISOLATE II miRNA, Plant miRNA, Biofluids RNA, RNA/DNA/Protein, and FFPE RNA/DNA Kits.